MPLT
MapLight Therapeutics, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-23 | Babler Martin |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. |
Stock Option (right to buy)
|
29,804 |
| 2026-06-23 | Walker Maria C |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. |
Stock Option (right to buy)
|
14,902 |
| 2026-06-23 | Walker Maria C |
Director |
Award↑
Filing footnotes — Voting Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
Voting Common Stock
|
3,932 |
| 2026-06-23 | Cox Troy |
Director |
Award↑
Filing footnotes — Voting Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
Voting Common Stock
|
7,864 |
| 2026-06-23 | Cox Troy |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-23 | Babler Martin |
Director |
Award↑
Filing footnotes — Voting Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
Voting Common Stock
|
7,864 |
| 2026-06-23 | Cox Troy |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest in three equal annual installments beginning on June 23, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. |
Stock Option (right to buy)
|
29,804 |
| 2026-06-23 | Luneborg Nanna Liebach |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. |
Stock Option (right to buy)
|
14,902 |
| 2026-06-23 | Pavlov George |
Director |
Award↑
Filing footnotes — Voting Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
Voting Common Stock
|
3,932 |
| 2026-06-23 | Pavlov George |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. |
Stock Option (right to buy)
|
14,902 |
| 2026-06-23 | Babler Martin |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-23 | Garnett Timothy John |
Director |
Award↑
Filing footnotes — Voting Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
Voting Common Stock
|
3,932 |
| 2026-06-23 | Garnett Timothy John |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents a stock option granted pursuant to the Plan. The shares subject to this stock option will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. |
Stock Option (right to buy)
|
14,902 |
| 2026-06-23 | Luneborg Nanna Liebach |
Director |
Award↑
Filing footnotes — Voting Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The RSUs will vest on the earlier of (i) June 23, 2027, or (ii) the date of the Issuer's next annual stockholder meeting, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of the applicable vesting date. This grant was made pursuant to the Issuer's non-employee director compensation policy. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. |
Voting Common Stock
|
3,932 |
| 2026-05-18 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.57 to $28.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
198 |
| 2026-05-18 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.565 to $27.4347 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
118,037 |
| 2026-05-11 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
5,890 |
| 2026-05-11 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
877 |
| 2026-05-11 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
342 |
| 2026-05-11 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.3045 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
6,871 |
| 2026-05-11 | Hanson Kristopher |
General Counsel |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.305 to $30.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
5,808 |
| 2026-05-11 | Hanson Kristopher |
General Counsel |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.183 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
846 |
| 2026-05-11 | Hanson Kristopher |
General Counsel |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.26 to $28.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
284 |
| 2026-05-11 | Hanson Kristopher |
General Counsel |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.305 to $30.2965 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
6,979 |
| 2026-05-08 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.12 to $29.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
3,205 |
| 2026-05-08 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.11 to $29.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
1,582 |
| 2026-05-08 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $28.1099 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
29,624 |
| 2026-05-07 | Foff Erin Pennock |
Chief Medical Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.08 to $29.045 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
4,321 |
| 2026-05-07 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.91 to $29.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
5,220 |
| 2026-05-07 | Lillie James Woodruff |
Chief Scientific Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.08 to $28.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
721 |
| 2026-05-07 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.885 to $28.8833 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
14,880 |
| 2026-05-07 | Foff Erin Pennock |
Chief Medical Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.09 to $29.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
117 |
| 2026-05-06 | Foff Erin Pennock |
Chief Medical Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
15,900 |
| 2026-05-06 | Lillie James Woodruff |
Chief Scientific Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
8,390 |
| 2026-05-06 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
8,098 |
| 2026-05-06 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
15,603 |
| 2026-05-06 | Foff Erin Pennock |
Chief Medical Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
8,152 |
| 2026-05-06 | Lillie James Woodruff |
Chief Scientific Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
16,421 |
| 2026-05-06 | Setia Vishwas |
Chief Financial Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.73 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
2,068 |
| 2026-05-06 | Setia Vishwas |
Chief Financial Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
8,496 |
| 2026-05-05 | Setia Vishwas |
Chief Financial Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
9,935 |
| 2026-05-05 | Foff Erin Pennock |
Chief Medical Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
931 |
| 2026-05-05 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
9,544 |
| 2026-05-05 | Lillie James Woodruff |
Chief Scientific Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
963 |
| 2026-05-05 | Setia Vishwas |
Chief Financial Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
968 |
| 2026-05-05 | Lillie James Woodruff |
Chief Scientific Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
10,132 |
| 2026-05-05 | Foff Erin Pennock |
Chief Medical Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
9,645 |
| 2026-05-05 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
928 |
| 2026-05-04 | Kroeger Christopher A. |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
5,427 |
| 2026-05-04 | Setia Vishwas |
Chief Financial Officer |
Sell↓
Filing footnotes — Voting Common Stock (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Voting Common Stock
|
787 |